dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gomez Lara, Josep |
dc.contributor.author | Oyarzabal, Loreto |
dc.contributor.author | Ortega-Paz, Luis |
dc.contributor.author | Brugaletta, Salvatore |
dc.contributor.author | Romaguera, Rafael |
dc.contributor.author | Salvatella, Neus |
dc.contributor.author | Otaegui Irurueta, Imanol |
dc.date.accessioned | 2022-05-31T07:18:53Z |
dc.date.available | 2022-05-31T07:18:53Z |
dc.date.issued | 2021-11-16 |
dc.identifier.citation | Gomez-Lara J, Oyarzabal L, Ortega-Paz L, Brugaletta S, Romaguera R, Salvatella N, et al. Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. J Am Heart Assoc. 2021 Nov 16;10(22):e022123. |
dc.identifier.issn | 2047-9980 |
dc.identifier.uri | https://hdl.handle.net/11351/7590 |
dc.description | Infart de miocardi; Disfunció endotelial; Tomografia de coherència òptica |
dc.description.sponsorship | The source funding of the 4 randomized trials included in this study is the following. The BVS‐FLOW trial (Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus‐eluting metallic stents: a randomised trial) was funded by a grant of “La Marato” Foundation. The Spanish Heart Foundation funded the RE‐TROFI2 (Long‐Term Coronary Functional Assessment of the Infarct‐Related Artery Treated With Everolimus‐Eluting Bioresorbable Scaffolds or Everolimus‐Eluting Metallic Stents: Insights of the TROFI II Trial) and MAGSTEMI (Magnesium‐Based Resorbable Scaffold Versus Permanent Metallic Sirolimus‐Eluting Stent in Patients With ST‐Segment Elevation Myocardial Infarction) trials. The FUNCOMBO (Coronary endothelial and microvascular function distal to polymer‐free and endothelial cell‐capturing drug‐eluting stents) trial was funded by OrbusNeich and was promoted by the Spanish Heart Foundation. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Journal of the American Heart Association;10(22) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Cor - Malalties - Tractament |
dc.subject | Medicaments - Alliberament retardat |
dc.subject | Cor - Malalties - Cirurgia |
dc.subject.mesh | Percutaneous Coronary Intervention |
dc.subject.mesh | Drug-Eluting Stents |
dc.subject.mesh | Coronary Disease |
dc.title | Coronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1161/JAHA.121.022123 |
dc.subject.decs | cirugía coronaria percutánea |
dc.subject.decs | stents liberadores de fármacos |
dc.subject.decs | enfermedad coronaria |
dc.relation.publishversion | https://doi.org/10.1161/JAHA.121.022123 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gomez-Lara J, Romaguera R] University Hospital of Bellvitge, Biomedical Resarch Institute of Bellvitge (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain. [Oyarzabal L] University Hospital of Bellvitge, Biomedical Resarch Institute of Bellvitge (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain. Clinic Hospital of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Ortega-Paz L, Brugaletta S] Clinic Hospital of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Salvatella N] Heart Disease Reseacrh Group, Mar Hospital, Biomedical Research Institute of Mar Hospital (IMIM), Barcelona, Spain. [Otaegui I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34729992 |
dc.identifier.wos | 000718875100023 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |